Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials 3 Hot on the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 4 Idiopathic Pulmonary Fibrosis: Lung Function is a Clinically Meaningful Endpoint for Phase 3 Trials 4 III. About Sarcoidosis 5 A Novel Sarcoidosis Risk Locus for Europeans on Chromosom...

Sarcoidosis is a systemic disease of unknown etiology. Skin lesions occur in about a quarter of patients with sarcoidosis and specific manifestations include erythema nodosum, maculopapular eruption, plaques, lupus pernio and scar sarcoidosis. A 39-year old male presented with cutaneous involvement of sarcoidosis. The skin biopsy revealed non-caseating granuloma. Our patient had skin manifestat...

INTRODUCTION Sarcoidosis is a multisystemic inflammatory disease with myriad clinical manifestations. Neurologic involvement in sarcoidosis is uncommon. Peripheral neuropathic presentations include mononeuropathy, mononeuritis multiplex, and generalized sensory, motor, autonomic, and sensorimotor polyneuropathies. CASE PRESENTATION We report a case of carpal tunnel syndrome caused by sarcoido...

BACKGROUND Infliximab, a TNF-alpha blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. DESIGN Case-report. RESULTS AND CONCLUSIONS A patient with severe earlobe sarcoidosis, treated with infliximab, is pr...

Sarcoidosis is an inflammatory disease involving multiple-organs with an unknown cause. The new onset of sarcoidosis associated with therapeutic agents has been observed in 3 clinical settings; tumor necrosis factor antagonists in autoimmune rheumatologic diseases, interferon alpha with or without ribavirin in patients with chronic hepatitis C or melanoma, and antineoplastic agent-associated sa...

Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmune reactions to infliximab. We report a case of a patient with advanced sarcoidosis who developed ...

Persistent lymphocytosis as a presenting sign in sarcoidosis is described in a 61-year-old man. Lymphocytosis is an unusual finding in sarcoidosis. The case presented seems to suggest that sarcoidosis should be considered in the differential diagnosis of lymphocytosis.

We read with interest the article by Shorr et al (September 2001),1 regarding the hyperreactive airway response (AHR) seen in the subgroup of nonsmoking patients with newly diagnosed sarcoidosis and endobronchial disease. Although the data are limited,1 (Table 1) if sarcoidosis is a given, the probability of the test (endobronchial biopsy) for diagnosing sarcoidosis approaches one if the patien...

OBJECTIVES To further identify the single-nucleotide polymorphisms (SNPs) that contribute to the genetic susceptibility to sarcoidosis, we examined the potential association between sarcoidosis and 15 SNPs of the ANXA11 gene. DESIGN A case-control study. SETTING A tuberculosis unit in a hospital of the university in China. PARTICIPANTS Participants included 412 patients with sarcoidosis a...

The Lung Allocation Score prioritizes lung transplantation candidates balancing waitlist-mortality and post-transplant survival. score groups sarcoidosis based on mean pulmonary artery pressure: ≤30 mmHg (Sarcoidosis A) are grouped with COPD >30 D) idiopathic fibrosis. We hypothesize that have a higher than other within their LAS grouping. This is retrospective cohort study of consecutive fr...